|
Sign In to gain access to subscriptions and/or personal tools.
|
Disease activity, cumulative damage and quality of life in systematic lupus erythematosus: results of a cross-sectional study
J.G. Hanly
Division of Rheumatology, Department of Medicine, Victoria General Hospital site of the Queen Elizabeth Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada
The relationship between disease activity, cumulative damage and self-reported quality of life was examined in 96 patients with Systematic Lupus Erythematosus (SLE).
Disease activity was measured by the SLE Disease Activity Index (SLEDAI) and cumulative damage by the Systematic Lupus International Cooperating Clinics/ACR damage index (DI). Quality of life was assessed by the Medical Outcomes Survey Short Form 20 (SF-20) self-report questionnaire which consists of six subscales.
The study population was predominantly Caucasian (91 %) and female (90%). The mean (± s.d.) age was 42.0 ± 11.0 years and disease duration was 7.5 ± 5.5 years. SLEDAI scores varied from 0-28, with a mean (± s.d.) of 4.8 ± 5.2. The mean (± s.d.) DI score was 0.74 ± 1.06, with a range of 0-5. Subscales of the SF-20 varied from 0-100 and the range of mean (± s.d.) scores varied from 35.0 ± 42.2 to 70.5 ± 28.7. There was no correlation between SLEDAI and DI scores or between SLEDAI scores and any of the six subscales of the SF-20. Likewise there was no correlation between DI scores and SF-20 subscales with the exception of Health perception (r = 0.34, P = 0.02).
These results indicate that there are at least three independent dimensions of health status in SLE, namely disease activity, cumulative damage and quality of life. Furthermore, the extent of inflammatory disease activity and irreversible target organ damage are not the sole determinants for quality of life in SLE patients.
Key Words: SLE • lupus • quality of life • damage • disease activity
Lupus, Vol. 6, No. 3,
243-247 (1997)
DOI: 10.1177/096120339700600305
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
S. APPENZELLER, A. E. CLARKE, P. PANOPALIS, L. JOSEPH, Y. ST. PIERRE, and T. LI
The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus
J Rheumatol,
May 1, 2009;
36(5):
947 - 952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G K Bertsias, J P A Ioannidis, J Boletis, S Bombardieri, R Cervera, C Dostal, J Font, I M Gilboe, F Houssiau, T Huizinga, et al.
EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints
Ann Rheum Dis,
April 1, 2009;
68(4):
477 - 483.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Bertsias, C Gordon, and D. Boumpas
Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future - the EULAR recommendations for the management of SLE and the use of end-points in clinical trials
Lupus,
May 1, 2008;
17(5):
437 - 442.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K Mcelhone, J Abbott, and L -S Teh
A review of health related quality of life in systemic lupus erythematosus
Lupus,
October 1, 2006;
15(10):
633 - 643.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. P. Leong, K. O. Kong, B. Y. H. Thong, E. T. Koh, T. Y. Lian, C. L. Teh, Y. K. Cheng, H. H. Chng, H. Badsha, W. G. Law, et al.
Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL)
Rheumatology,
October 1, 2005;
44(10):
1267 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L N Moorthy, M J Harrison, M Peterson, K B Onel, and T J. Lehman
Relationship of quality of life and physical function measures with disease activity in children with systemic lupus erythematosus
Lupus,
April 1, 2005;
14(4):
280 - 287.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A H Seawell and S Danoff-Burg
Psychosocial research on systemic lupus erythematosus: a literature review
Lupus,
December 1, 2004;
13(12):
891 - 899.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Jolly and T O Utset
Can disease specific measures for systemic lupus erythematosus predict patients health related quality of life?
Lupus,
December 1, 2004;
13(12):
924 - 926.
[Abstract]
[PDF]
|
|
|
|
|
|
|
S. Khanna, H. Pal, R. M. Pandey, and R. Handa
The relationship between disease activity and quality of life in systemic lupus erythematosus
Rheumatology,
December 1, 2004;
43(12):
1536 - 1540.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L N. Moorthy, L Robbins, M J Harrison, M G. Peterson, N Cox, K B Onel, and T J. Lehman
Quality of life in paediatric lupus
Lupus,
April 1, 2004;
13(4):
234 - 240.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V Strand, C Aranow, M H Cardiel, D Alarcon-Segovia, R Furie, Y Sherrer, J Tumlin, D J Wallace, LJP 394 Investigator Consortium, and B Crawford
Improvement in health-related quality of life in systemic lupus erythematosus patients enrolled in a randomized clinical trial comparing LJP 394 treatment with placebo
Lupus,
September 1, 2003;
12(9):
677 - 686.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N A Dayal, C Gordon, L Tucker, and D A Isenberg
The SLICC Damage Index: past, present and future
Lupus,
April 1, 2002;
11(4):
261 - 265.
[PDF]
|
|
|
|
|
|
|
D D Gladman and M. B Urowitz
The SLICC/ACR damage index: progress report and experience in the field
Lupus,
October 1, 1999;
8(8):
632 - 637.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. C Yen, C. Neville, and P. R Fortin
Discordance between patients and their physicians in the assessment of lupus disease activity: relevance for clinical trials
Lupus,
October 1, 1999;
8(8):
660 - 670.
[Abstract]
[PDF]
|
|
|
|
|
